Immune responses to AAV in clinical trials.

Recent findings in a clinical trial in which an adeno-associated virus (AAV) vector expressing coagulation factor IX (F.IX) was introduced into the liver of hemophilia B subjects highlighted a new issue previously not identified in animal studies. Upon AAV gene transfer to liver, two subjects enrolled in this trial developed transient elevation of liver enzymes, likely as a consequence of immune rejection of transduced hepatocytes mediated by AAV capsid-specific CD8(+) T cells. Studies in healthy donors showed that humans carry a population of antigen-specific memory CD8(+) T cells probably arising from wild-type AAV infections. The hypothesis formulated here is that these cells expanded upon re-exposure to capsid, i.e. upon AAV-2 hepatic gene transfer, and cleared AAV epitope-bearing transduced hepatocytes. Other hypotheses have been formulated which include specific receptor-binding properties of AAV-2 capsid, presence of capsid-expressing DNA in AAV vector preparations, and expression of alternative reading frames from the transgene. Absence of a valid animal model has prevented an in-depth mechanistic study of the phenomenon. Several possible solutions to the problem are discussed, including the administration of a short-term anti-T cell immunosuppression regimen concomitant with gene transfer. While more studies will be necessary to further define mechanisms and risks associated with capsid-specific immune responses in humans, monitoring of these responses in clinical trials will be essential to achieving the goal of long-term therapeutic gene transfer in humans.

[1]  J. F. Wright,et al.  Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. , 2007, Blood.

[2]  C. Miao.  Recent advances in immune modulation. , 2007, Current gene therapy.

[3]  R. Mandel,et al.  Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions. , 2007, Current gene therapy.

[4]  Thomas Ferkol,et al.  Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. , 2007, Human gene therapy.

[5]  R. Herzog,et al.  Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. , 2007, Blood.

[6]  Aarati R. Ranade,et al.  Robust expansion of human hepatocytes in Fah−/−/Rag2−/−/Il2rg−/− mice , 2007, Nature Biotechnology.

[7]  D. DiMichele.  Inhibitor development in haemophilia B: an orphan disease in need of attention , 2007, British journal of haematology.

[8]  R. Samulski,et al.  Adeno-Associated Virus Type 2 (AAV2) Capsid-Specific Cytotoxic T Lymphocytes Eliminate Only Vector-Transduced Cells Coexpressing the AAV2 Capsid In Vivo , 2007, Journal of Virology.

[9]  Lili Wang,et al.  Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets. , 2007, Human gene therapy.

[10]  Z. Xiang,et al.  Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  Marcela V Maus,et al.  CD8+ T-cell responses to adeno-associated virus capsid in humans , 2007, Nature Medicine.

[12]  J. F. Wright,et al.  Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography. , 2007, Journal of virological methods.

[13]  J. Gray,et al.  Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. , 2007, Blood.

[14]  J. Wilson,et al.  Efficacy and safety of adeno‐associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy , 2006, Journal of thrombosis and haemostasis : JTH.

[15]  Sihong Song,et al.  Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults. , 2006, Human gene therapy.

[16]  J. Sommer,et al.  Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. , 2006, Blood.

[17]  L. Naldini,et al.  Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice. , 2006, The Journal of clinical investigation.

[18]  Nicki Panoskaltsis,et al.  Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. , 2006, The New England journal of medicine.

[19]  M. Ozelo,et al.  Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  S. Akira,et al.  Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling. , 2006, The Journal of clinical investigation.

[21]  Ravi A. Desai,et al.  Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid , 2006, Nature Medicine.

[22]  L. Couto,et al.  Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. , 2006, Blood.

[23]  R. Hebbel,et al.  Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor. , 2006, Blood.

[24]  J. Sommer,et al.  Inadvertent germline transmission of AAV2 vector: findings in a rabbit model correlate with those in a human clinical trial. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[25]  F. Bosch,et al.  Reversal of Type 1 Diabetes by Engineering a Glucose Sensor in Skeletal Muscle , 2006, Diabetes.

[26]  A. Varki,et al.  Loss of Siglec expression on T lymphocytes during human evolution , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[27]  L. Naldini,et al.  Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer , 2006, Nature Medicine.

[28]  R. Herzog,et al.  Treatment of human disease by adeno-associated viral gene transfer , 2006, Human Genetics.

[29]  C. Norbury.  Drinking a lot is good for dendritic cells , 2006, Immunology.

[30]  J. Emerson,et al.  Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors. , 2006, Human gene therapy.

[31]  Geoffrey Kemball-Cook,et al.  Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. , 2006, Blood.

[32]  J. Rasko,et al.  Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response , 2006, Nature Medicine.

[33]  D. Schaffer,et al.  Directed evolution of adeno-associated virus yields enhanced gene delivery vectors , 2006, Nature Biotechnology.

[34]  Wenman Wu,et al.  Efficient AAV1-AAV2 hybrid vector for gene therapy of hemophilia. , 2006, Human gene therapy.

[35]  A. Salvetti,et al.  Evidence for encapsidation of prokaryotic sequences during recombinant adeno-associated virus production and their in vivo persistence after vector delivery. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[36]  T. Flotte.  Recent developments in recombinant AAV-mediated gene therapy for lung diseases. , 2005, Current gene therapy.

[37]  P. Tak,et al.  Enhanced gene transfer to arthritic joints using adeno-associated virus type 5: implications for intra-articular gene therapy , 2005, Annals of the rheumatic diseases.

[38]  H. Stedman,et al.  Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. , 2005, Blood.

[39]  Luis Garcia,et al.  Rescue of Dystrophic Muscle Through U7 snRNA-Mediated Exon Skipping , 2004, Science.

[40]  R. Herzog,et al.  Therapeutic levels of factor IX expression using a muscle-specific promoter and adeno-associated virus serotype 1 vector. , 2004, Human gene therapy.

[41]  R. Herzog,et al.  Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer. , 2004, Blood.

[42]  A. Annoni,et al.  Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. , 2004, Blood.

[43]  Cameron S. Osborne,et al.  LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1 , 2003, Science.

[44]  Yuqin Wang,et al.  Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. , 2003, The Journal of clinical investigation.

[45]  Alan McClelland,et al.  AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. , 2003, Blood.

[46]  K. High.  The risks of germline gene transfer. , 2003, The Hastings Center report.

[47]  R. Herzog,et al.  Improved Hepatic Gene Transfer by Using an Adeno-Associated Virus Serotype 5 Vector , 2002, Journal of Virology.

[48]  G. Aguirre,et al.  Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Lili Wang,et al.  Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Lung-Ji Chang,et al.  RNA 3′ Readthrough of Oncoretrovirus and Lentivirus: Implications for Vector Safety and Efficacy , 2002, Journal of Virology.

[51]  A. Mortellaro,et al.  Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning , 2002, Science.

[52]  A. Fischer,et al.  Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. , 2002, The New England journal of medicine.

[53]  R. Herzog,et al.  Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. , 2002, Blood.

[54]  N. Boyce.  Trial halted after gene shows up in semen , 2001, Nature.

[55]  K. High.  AAV‐Mediated Gene Transfer for Hemophilia , 2001, Annals of the New York Academy of Sciences.

[56]  D. McCarty,et al.  Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis , 2001, Gene Therapy.

[57]  Theresa A. Storm,et al.  Extrachromosomal Recombinant Adeno-Associated Virus Vector Genomes Are Primarily Responsible for Stable Liver Transduction In Vivo , 2001, Journal of Virology.

[58]  Jean Bennett,et al.  Gene therapy restores vision in a canine model of childhood blindness , 2001, Nature Genetics.

[59]  Alan McClelland,et al.  Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector , 2000, Nature Genetics.

[60]  J. Schlehofer,et al.  Update on the prevalence of serum antibodies (IgG and IgM) to adeno‐associated virus (AAV) , 1999, Journal of medical virology.

[61]  K. Propert,et al.  Immune responses to adenovirus and adeno-associated virus in humans , 1999, Gene Therapy.

[62]  T. Flotte,et al.  Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[63]  Prerna Sharma,et al.  Circular Intermediates of Recombinant Adeno-Associated Virus Have Defined Structural Characteristics Responsible for Long-Term Episomal Persistence in Muscle Tissue , 1998, Journal of Virology.

[64]  L. Villarreal,et al.  Adeno-associated virus vectors can be efficiently produced without helper virus , 1998, Gene Therapy.

[65]  James M. Wilson,et al.  Transduction of Dendritic Cells by DNA Viral Vectors Directs the Immune Response to Transgene Products in Muscle Fibers , 1998, Journal of Virology.

[66]  James M. Wilson,et al.  Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[67]  T. Palmer,et al.  Production of human factor IX in animals by genetically modified skin fibroblasts: potential therapy for hemophilia B. , 1989, Blood.

[68]  R. Samulski,et al.  Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[69]  D. Duan,et al.  Efficient Whole-body Transduction with Trans-splicing Adeno-associated Viral Vectors. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[70]  R. Herzog,et al.  Posttranslational modifications of recombinant myotube-synthesized human factor IX. , 2001, Blood.

[71]  Katherine A. High,et al.  Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector , 1999, Nature Medicine.